Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Phytocannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), are bioactive compounds found in Cannabis sativa and related plants. There is substantial scientific interest and growing evidence supporting their impact on the neurotransmitter system. Phytocannabinoids primarily exert their effects by interacting with the endocannabinoid system (ECS), particularly the CB1 and CB2 receptors, which are widely expressed in the central and peripheral nervous systems. Activation of these receptors modulates the release of various neurotransmitters, including dopamine, serotonin, glutamate, and GABA, thereby influencing mood, anxiety, pain perception, and other neurological functions.

Clinical and preclinical studies have shown that phytocannabinoids can alter neurotransmitter signaling, with CBD displaying anxiolytic, antipsychotic, and neuroprotective effects, while THC has psychoactive properties that are mediated by its action on CB1 receptors. For example, research published in journals such as Neurotherapeutics and Frontiers in Pharmacology has documented the modulatory role of phytocannabinoids on neurotransmitter release and synaptic plasticity. Approved medications like Epidiolex (CBD) and Sativex (THC/CBD) further validate their neurological impact for certain conditions.

While more research is needed to fully elucidate the mechanisms and long-term effects, current scientific evidence justifies the use of phytocannabinoids to support the neurotransmitter system, especially in the context of certain neurological and psychiatric disorders.

More about phytocannabinoids
More about Specific Neurotransmitters

Other ingredients that support Specific Neurotransmitters

Other body systems supported by phytocannabinoids

Products containing phytocannabinoids